Investigation of Paraoxonase-1 Genotype and Enzyme-Kinetic Parameters in the Context of Cognitive Impairment in Parkinson’s Disease

• Published in: Antioxidants Vol. 12; no. 2; p. 399
• Main Authors: Petrič, Boštjan, Redenšek Trampuž, Sara, Dolžan, Vita, Gregorič Kramberger, Milica, Trošt, Maja, Maraković, Nikola, Goličnik, Marko, Bavec, Aljoša
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 07.02.2023; MDPI
• Subjects: algorithms; Alzheimer's disease; aryldialkylphosphatase; Biomarkers; cognition; Cognitive ability; cognitive disorders; cognitive impairment; Dementia; Dementia disorders; Enzyme kinetics; genotype; Hallucinations; High density lipoprotein; Homocysteine; iFIT; Movement disorders; Neurodegenerative diseases; Oxidative stress; Paraoxonase; Paraoxonase 1; paraoxonase activity; Parkinson disease; Parkinson's disease; Patients; Physiological aspects; Plasma; Single-nucleotide polymorphism; single-nucleotide polymorphisms; United States; paraoxonase 1; Parkinson disease; iFIT; cognitive impairment; paraoxonase activity; single-nucleotide polymorphisms

Cognitive impairment is a common non-motor symptom of Parkinson’s disease (PD), which often progresses to PD dementia. PD patients with and without dementia may differ in certain biochemical parameters, which could thus be used as biomarkers for PD dementia. The enzyme paraoxonase 1 (PON1) has previ...